Annamycin cardiac safety now peer-reviewed
www.merlintrader.com/moleculin-bi...
www.merlintrader.com/moleculin-bi...
Moleculin ($MBRX): Preclinical Pancreatic Cancer Data
Moleculin $MBRX: AACR pancreatic cancer findings are preclinical, not a clinical pancreas program or new MIRACLE AML efficacy readout.
www.merlintrader.com
September 28, 2026 at 4:44 PM
Annamycin cardiac safety now peer-reviewed
www.merlintrader.com/moleculin-bi...
www.merlintrader.com/moleculin-bi...
🚨 $MBRX
On June 30, 2026, Moleculin Biotech, Inc. , issued a press release which announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
On June 30, 2026, Moleculin Biotech, Inc. , issued a press release which announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
SEC Filing: MBRX
Click to view the official SEC document.
www.sec.gov
September 28, 2026 at 11:01 AM
🚨 $MBRX
On June 30, 2026, Moleculin Biotech, Inc. , issued a press release which announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
On June 30, 2026, Moleculin Biotech, Inc. , issued a press release which announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
🚨 $MBRX
On September 29, 2026, Moleculin Biotech, Inc. , issued a press release which announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or r...
On September 29, 2026, Moleculin Biotech, Inc. , issued a press release which announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or r...
SEC Filing: MBRX
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 12:46 PM
🚨 $MBRX
On September 29, 2026, Moleculin Biotech, Inc. , issued a press release which announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or r...
On September 29, 2026, Moleculin Biotech, Inc. , issued a press release which announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or r...
#MBRX Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
https://www.stocktitan.net/news/MBRX/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-ua8g4hxcsvtj.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-ua8g4hxcsvtj.html?utm_source=stocktitan-bluesky&utm_medium=social
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 28, 2026 at 11:00 AM
#MBRX Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
https://www.stocktitan.net/news/MBRX/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-ua8g4hxcsvtj.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-ua8g4hxcsvtj.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $MBRX
On September 25, 2026, Moleculin Biotech, Inc. , issued a press release which announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
On September 25, 2026, Moleculin Biotech, Inc. , issued a press release which announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
SEC Filing: MBRX
Click to view the official SEC document.
www.sec.gov
September 25, 2026 at 5:07 PM
🚨 $MBRX
On September 25, 2026, Moleculin Biotech, Inc. , issued a press release which announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
On September 25, 2026, Moleculin Biotech, Inc. , issued a press release which announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
#MBRX Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-oj7x211r18fn.html
https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-oj7x211r18fn.html
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin (Nasdaq: MBRX) announced that CEO Walter Klemp appeared in a Virtual Investor “What This Means” segment.He discussed reaching enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in adult R/R AML, and preparations for interim data unblinding targeted for mid-2026.
www.stocktitan.net
June 4, 2026 at 12:31 PM
#MBRX Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-oj7x211r18fn.html
https://www.stocktitan.net/news/MBRX/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-oj7x211r18fn.html
#MBRX Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
https://www.stocktitan.net/news/MBRX/annamycin-turns-cold-pancreatic-tumors-hot-in-new-preclinical-data-us7aq8516g51.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/annamycin-turns-cold-pancreatic-tumors-hot-in-new-preclinical-data-us7aq8516g51.html?utm_source=stocktitan-bluesky&utm_medium=social
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 25, 2026 at 5:05 PM
#MBRX Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
https://www.stocktitan.net/news/MBRX/annamycin-turns-cold-pancreatic-tumors-hot-in-new-preclinical-data-us7aq8516g51.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/annamycin-turns-cold-pancreatic-tumors-hot-in-new-preclinical-data-us7aq8516g51.html?utm_source=stocktitan-bluesky&utm_medium=social
I did pick up some but focused more on $mbrx, $aqst, $iova and $pdsb
November 20, 2024 at 9:38 PM
I did pick up some but focused more on $mbrx, $aqst, $iova and $pdsb
I've got to go do something productive but keep the hits coming. In the meantime, here's one from '09 that sounds good and made me laugh. @dlynch.bsky.social @paulheardartist.bsky.social @jmareditor.bsky.social @milesgeffin.bsky.social @beefreeferlives.bsky.social www.youtube.com/watch?v=MBRX...
Datarock - True Stories [Official Music Video]
YouTube video by NettwerkMusic
www.youtube.com
November 8, 2024 at 9:36 PM
I've got to go do something productive but keep the hits coming. In the meantime, here's one from '09 that sounds good and made me laugh. @dlynch.bsky.social @paulheardartist.bsky.social @jmareditor.bsky.social @milesgeffin.bsky.social @beefreeferlives.bsky.social www.youtube.com/watch?v=MBRX...
News; ( NASDAQ: #MBRX ) Moleculin Announces Pricing of up to $16.5 Million Public Offering
#StockMarket #News
#StockMarket #News
August 16, 2024 at 7:35 PM
News; ( NASDAQ: #MBRX ) Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
#StockMarket #News
#StockMarket #News
October 7, 2024 at 3:55 PM
Moleculin (#$MBRX): Nasdaq Delisting Determination, Hearing Request Planned
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/moleculin-bi...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/moleculin-bi...
September 23, 2026 at 11:37 AM
Moleculin (#$MBRX): Nasdaq Delisting Determination, Hearing Request Planned
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/moleculin-bi...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/moleculin-bi...
There seem to be very good #biotech #stock opportunities. Data from $mbrx, $mreo, $pdsb, $aqst, $iova, $oncy all look good and their valuations give them more upside probability and magnitude than downside. $mbrx, $oncy and $pdsb should be valued at 3x more market cap at the least
November 20, 2024 at 1:35 AM
🚨 $MBRX
On September 23, 2026, Moleculin Biotech, Inc. , issued a press release which announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin tec...
On September 23, 2026, Moleculin Biotech, Inc. , issued a press release which announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin tec...
SEC Filing: MBRX
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 12:26 PM
🚨 $MBRX
On September 23, 2026, Moleculin Biotech, Inc. , issued a press release which announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin tec...
On September 23, 2026, Moleculin Biotech, Inc. , issued a press release which announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin tec...
BREAKING NEWS: ( NASDAQ: #MBRX ) Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
#StockMarket #News
#StockMarket #News
September 23, 2024 at 2:25 PM
#MBRX Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
https://www.stocktitan.net/news/MBRX/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-yxqa7k1khsf4.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-yxqa7k1khsf4.html?utm_source=stocktitan-bluesky&utm_medium=social
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Moleculin Biotech (MBRX) received Mexican Patent No. 436849 covering its proprietary lung-targeted liposomal Annamycin technology, extending protection in Mexico until November 23, 2040.The patent reinforces a growing global intellectual property estate around Annamycin, a novel anthracycline being evaluated in the pivotal MIRACLE Phase 2/3 trial for relapsed or refractory acute myeloid leukemia (AML). The patented liposomal formulation is designed to enhance delivery of Annamycin to pulmonary tumors and metastatic disease, supporting potential use beyond hematologic cancers. Management describes strong international patent coverage as central to protecting the long-term commercial opportunity of the Annamycin platform.
www.stocktitan.net
September 23, 2026 at 12:25 PM
#MBRX Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
https://www.stocktitan.net/news/MBRX/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-yxqa7k1khsf4.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MBRX/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-yxqa7k1khsf4.html?utm_source=stocktitan-bluesky&utm_medium=social
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 10:28:19 ET on NASDAQ | 2026-07-31
July 31, 2026 at 2:33 PM
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 10:28:19 ET on NASDAQ | 2026-07-31
Trading Halted for $MBRX Moleculin Biotech, Inc. COM | at 10:23:19.140 ET on NASDAQ | Volatility Trading Pause | 2026-07-31
July 31, 2026 at 2:28 PM
Trading Halted for $MBRX Moleculin Biotech, Inc. COM | at 10:23:19.140 ET on NASDAQ | Volatility Trading Pause | 2026-07-31
NEWS: ( NASDAQ: #MBRX ) Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
#StockMarket #News
#StockMarket #News
August 14, 2024 at 6:50 PM
JUST IN: ( NASDAQ: #MBRX ) Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
#StockMarket #News
#StockMarket #News
August 26, 2024 at 7:20 PM
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 13:36:59 ET on NASDAQ | 2025-02-13
February 13, 2025 at 6:38 PM
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 13:36:59 ET on NASDAQ | 2025-02-13
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 13:14:56 ET on NASDAQ | 2025-02-13
February 13, 2025 at 6:18 PM
Trading Resumed for $MBRX Moleculin Biotech, Inc. COM | at 13:14:56 ET on NASDAQ | 2025-02-13